pivalde: "... IMO the "Rubidium" paper changed totally the competition to find a drug for AD and in this competition Prana is at the moment No 1. But it is also No 1 in finding a drug for mitochondria diseases what is much bigger issue than AD."
I agree with your assessment, pivalde, thanks.
" PBT2 for acute indications ", page-6
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(25.0%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.3¢ | $4.734K | 1.341M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 49 | 30295639 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 129917446 | 34 |
View Market Depth
| Last trade - 15.44pm 15/10/2024 (20 minute delay) ? |
| ATH (ASX) Chart |